These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 32173275)

  • 1. Sharing the costs of structural interventions: What can models tell us?
    Stuart RM; Wilson DP
    Int J Drug Policy; 2021 Feb; 88():102702. PubMed ID: 32173275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financing structural interventions: going beyond HIV-only value for money assessments.
    Remme M; Vassall A; Lutz B; Luna J; Watts C
    AIDS; 2014 Jan; 28(3):425-34. PubMed ID: 24670525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financing intersectoral action for health: a systematic review of co-financing models.
    McGuire F; Vijayasingham L; Vassall A; Small R; Webb D; Guthrie T; Remme M
    Global Health; 2019 Dec; 15(1):86. PubMed ID: 31849335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining HIV programmes for seasonal migrant labourers.
    Kelly SL; Shattock AJ; Kerr CC; Stuart RM; Papoyan A; Grigoryan T; Hovhannisyan R; Grigoryan S; Benedikt C; Wilson DP
    J Int AIDS Soc; 2016; 19(1):20772. PubMed ID: 27281790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using allocative efficiency analysis to inform health benefits package design for progressing towards Universal Health Coverage: Proof-of-concept studies in countries seeking decision support.
    Fraser-Hurt N; Hou X; Wilkinson T; Duran D; Abou Jaoude GJ; Skordis J; Chukwuma A; Lao Pena C; Tshivuila Matala OO; Gorgens M; Wilson DP
    PLoS One; 2021; 16(11):e0260247. PubMed ID: 34843546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of constraints on the efficient allocation of resources for HIV prevention.
    Stopard IJ; McGillen JB; Hauck K; Hallett TB
    AIDS; 2019 Jun; 33(7):1241-1246. PubMed ID: 30649065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice.
    Alistar SS; Brandeau ML
    Med Decis Making; 2012; 32(1):105-17. PubMed ID: 21191118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Thresholds in Global Health: Taking a Multisectoral Perspective.
    Remme M; Martinez-Alvarez M; Vassall A
    Value Health; 2017 Apr; 20(4):699-704. PubMed ID: 28408014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A benefit-cost analysis of syringe exchange programs.
    Reid RJ
    J Health Soc Policy; 2000; 11(4):41-57. PubMed ID: 10620865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.
    Degenhardt L; Mathers BM; Wirtz AL; Wolfe D; Kamarulzaman A; Carrieri MP; Strathdee SA; Malinowska-Sempruch K; Kazatchkine M; Beyrer C
    Int J Drug Policy; 2014 Jan; 25(1):53-60. PubMed ID: 24113623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diplomacy and Health: The End of the Utilitarian Era.
    Kevany S; Matthews M
    Int J Health Policy Manag; 2017 Apr; 6(4):191-194. PubMed ID: 28812802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey.
    Nguyen QL; Nguyen LH; Tran BX; Phan HT; Le HT; Nguyen HD; Tran TD; Do CD; Nguyen CM; Thuc VT; Latkin C; Zhang MW; Ho RC
    PLoS One; 2017; 12(2):e0172050. PubMed ID: 28199405
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.